Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 June 2006, Vol. 107, No. 12, pp. 4841-4848.
Prepublished online as a Blood First Edition Paper on March 2, 2006; DOI 10.1182/blood-2005-10-4044.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-10-4044v1
107/12/4841    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermann-Kleiter, N.
Right arrow Articles by Baier, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermann-Kleiter, N.
Right arrow Articles by Baier, G.
Related Collections
Right arrow Immunobiology
Right arrow Signal Transduction
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

IMMUNOBIOLOGY

PKC{theta} and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes

Natascha Hermann-Kleiter, Nikolaus Thuille, Christa Pfeifhofer, Thomas Gruber, Michaela Schäfer, Christof Zitt, Armin Hatzelmann, Christian Schudt, Michael Leitges, and Gottfried Baier

From the Department for Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria; ALTANA Pharma, Konstanz, Germany; and Medical University, Hanover, Germany.

We here investigate the crosstalk of PKC and PKA signaling during primary CD3+ T-lymphocyte activation using pharmacologic inhibitors and activators in combination with our established panel of PKC isotype–deficient mouse T cells in vitro. PKC{theta} and PKA inversely affect the CD3/CD28-induced IL-2 expression, whereas other PKC isotypes are dispensable in this signaling pathway. Gene ablation of PKC{theta} selectively results in a profound reduction of IL-2 production; however, complete abrogation of IL-2 production in these PKC{theta}–/– T cells was achieved only by simultaneous coactivation of the cAMP/PKA pathway in CD3+ T cells. Conversely, the reduced IL-2 production in PKC inhibitor–treated T cells can be rescued by inhibition of the cAMP/PKA pathway in wild-type but not in PKC{theta}–/– T cells. Mechanistically, the cAMP/PKA and PKC{theta} pathways converge at the level of NF-AT, as shown by DNA binding analysis. The combined increase in PKA and decrease in PKC{theta} activity leads to an enhanced inhibition of nuclear NF-AT translocation. This PKC{theta}/PKA crosstalk significantly affects neither the NF-{kappa}B, the AP-1, nor the CREB pathways. Taken together, this opposite effect between the positive PKC{theta} and the negative cAMP/PKA signaling pathways appears rate limiting for NF-AT transactivation and IL-2 secretion responses of CD3+ T lymphocytes.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J.-P. Evenou, J. Wagner, G. Zenke, V. Brinkmann, K. Wagner, J. Kovarik, K. A. Welzenbach, G. Weitz-Schmidt, C. Guntermann, H. Towbin, et al.
The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation
J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 792 - 801.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
T. Gruber, N. Hermann-Kleiter, R. Hinterleitner, F. Fresser, R. Schneider, G. Gastl, J. M. Penninger, and G. Baier
PKC-{theta} Modulates the Strength of T Cell Responses by Targeting Cbl-b for Ubiquitination and Degradation
Sci. Signal., June 23, 2009; 2(76): ra30 - ra30.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Norambuena, C. Metz, L. Vicuna, A. Silva, E. Pardo, C. Oyanadel, L. Massardo, A. Gonzalez, and A. Soza
Galectin-8 Induces Apoptosis in Jurkat T Cells by Phosphatidic Acid-mediated ERK1/2 Activation Supported by Protein Kinase A Down-regulation
J. Biol. Chem., May 8, 2009; 284(19): 12670 - 12679.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Letschka, V. Kollmann, C. Pfeifhofer-Obermair, C. Lutz-Nicoladoni, G. J. Obermair, F. Fresser, M. Leitges, N. Hermann-Kleiter, S. Kaminski, and G. Baier
PKC-{theta} selectively controls the adhesion-stimulating molecule Rap1
Blood, December 1, 2008; 112(12): 4617 - 4627.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
T. Bopp, C. Becker, M. Klein, S. Klein-Hessling, A. Palmetshofer, E. Serfling, V. Heib, M. Becker, J. Kubach, S. Schmitt, et al.
Cyclic adenosine monophosphate is a key component of regulatory T cell mediated suppression
J. Exp. Med., June 11, 2007; 204(6): 1303 - 1310.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020